Introduction {#s1}
============

Mounting clinical evidence suggests a key role for aldosterone in the progression of nephropathy. Inhibitors of the renin-angiotensin-aldosterone system (RAAS), such as angiotensin receptor blockers (ARB) and angiotensin-converting enzyme inhibitors (ACEI) have been demonstrated to delay the onset of macroalbuminuria or frank nephropathy in diabetics (Brenner et al., [@B9]; Lewis et al., [@B30]; Parving et al., [@B38]; Remuzzi et al., [@B42]; Ruggenenti et al., [@B44]). Nonetheless, a significant proportion of patients continue to progress to macroalbuminuria and overt nephropathy (Parving et al., [@B38]; Ruggenenti et al., [@B44]). Many patients on ACEI or ARB treatment exhibit "aldosterone escape," whereby the initial response of decreased aldosterone and urinary albumin to creatinine ratio (UACR) is followed by a rebound of aldosterone and reversion of UACR to pre-treatment levels (Lijnen et al., [@B31]; Pitt, [@B40]). The mineralocorticoid receptor (MR) antagonist spironolactone effectively reduced UACR in diabetic nephropathy patients exhibiting "aldosterone escape" while on ACEI therapy (Sato et al., [@B45]). Moreover, eplerenone, another marketed MR antagonist, decreased UACR in type 2 diabetics with mild to moderate nephropathy to a greater extent than that achieved with ACEI treatment alone, and independently of changes in blood pressure (Epstein, [@B13]; Epstein et al., [@B14]). However, inhibition of the RAAS with ACEI, ARB, direct renin inhibitors (DRI) or MR antagonists especially in dual or triple combination, increased the risk of hyperkalemia in patients with heart failure (HF), or chronic kidney disease (McMahon, [@B33]; Sica, [@B46]; Palmer, [@B37]; Weir and Rolfe, [@B52]).

Aldosterone regulates Na^+^ and K^+^ balance and hence extracellular fluid volume and blood pressure (Levy et al., [@B29]; Muldowney et al., [@B34]). Under conditions of low blood volume or reduced renal perfusion, plasma angiotensin II (angII) and K^+^ levels increase and synergistically stimulate aldosterone secretion from the adrenals thereby promoting Na^+^ and water retention in the proximal tubule and driving sodium-dependent K^+^ secretion in the distal tubule of the kidney (Palmer, [@B37]). Thus, when renal filtration is severely compromised, as in patients with chronic kidney disease (CKD), cardiometabolic syndrome or HF, Na^+^ reabsorption in the proximal tubule becomes highly efficient. Under these conditions, urinary volume and Na^+^ delivery to the distal tubule become rate limiting for Na^+^-dependent K^+^ secretion and hyperkalemia may ensue (Palmer, [@B37]). Plasma aldosterone is increased in some patients with CKD (Berl et al., [@B3]; Hene et al., [@B21]), diabetes (Hollenberg et al., [@B22]), and metabolic syndrome (Bochud et al., [@B7]), and plasma aldosterone correlates positively with UACR (Bianchi et al., [@B5]) and negatively with glomerular filtration rates (GFR) in CKD patients (Quinkler et al., [@B41]). However, and given the pivotal role of aldosterone in regulating K^+^ excretion, the beneficial UACR lowering effect of MR antagonists may be offset by an increased risk of hyperkalemia. Therefore, a MR antagonist that decreases UACR without increasing the risk of hyperkalemia would be highly desirable for the treatment and prevention of diabetic nephropathy.

PF-03882845 is a selective and potent non-steroidal MR antagonist. To determine whether PF-03882845 differentiates from traditional steroidal MR antagonists, we sought to investigate the effect of PF-03882845 on UACR and electrolyte balance in preclinical studies. The concentration effect curves for the prevention of increases in UACR and for elevation of serum K^+^ were established for PF-03882845 and eplerenone in a rat model of aldosterone-induced renal damage. Additionally, the effect of the compounds on urinary Na^+^/K^+^ ratio, a surrogate biomarker for electrolyte disturbances, was investigated. Our data indicate a larger therapeutic index, calculated as the ratio of the EC~50~ for increasing serum K^+^ or urinary Na^+^/K^+^ to the EC~50~ for UACR lowering, for PF-03882845 compared to eplerenone.

Materials and methods {#s2}
=====================

All procedures were conducted in accordance with Institutional Animal Care and Use Committee (IACUC) guidelines and regulations at Pfizer Inc (Groton, CT).

Selectivity and potency of PF-03882845 and eplerenone
-----------------------------------------------------

Huh7 cells were transiently transfected with a luciferase reporter gene under the control of a Gal4 response element (Gal4-RE-luc) and a plasmid containing the Gal4 DNA binding domain fused to MR ligand binding domain (Gal4-MR-LBD). Transfected cells were treated for 24 h with the EC~80~ concentration of activating ligand in the presence or absence of PF-03882845 or eplerenone in serum free medium. Luciferase activity was measured and the IC~50~ determined for each compound.

Effect of chronic administration of eplerenone and PF-03882845 on aldosterone-mediated renal injury
---------------------------------------------------------------------------------------------------

### Study A

Fifty five male uninephrectomized Sprague Dawley (SD) rats (Charles River, MA) were singly housed and provided food and water *ad-libitum*. Following an acclimation period, baseline 24 h urine samples were collected and analyzed for albumin and creatinine measurement. Baseline blood was taken by tail bleed for measurement of serum K^+^. Rats were then randomized into 5 groups. Four groups of rats (*n* = 11 per group) were implanted subcutaneously (SC) with Alzet mini-pumps (Alzet, Cupertino, CA) to deliver 2.5 μ L/h aldosterone (0.75 μ g/h) in 0.01% dimethylsulfoxide (DMSO) under isoflurane anesthesia. One group was sham operated (Veh Sham, *n* = 11). Immediately post-surgery, all rats were switched to a 6% high salt diet (Teklad TD.90230) and water containing 0.3% KCl *ad-libitum*. The following day, treatment with eplerenone was initiated in the 4 groups of rats that were implanted with aldosterone mini-pumps. Rats received either vehicle (Veh Aldo), or one of 3 doses of eplerenone: 15, 50, or 450 mg/kg BID by oral gavage. The sham-operated group also received vehicle (Veh Sham). Dosing was performed at 6 am and 4 pm for a duration of 27 days. Eplerenone was dissolved in vehicle comprised of 0.5% methyl cellulose, 0.1% polysorbate 80 in water.

### Study B

For study B the same protocol as study A was used, but PF-03882845 was administered in lieu of eplerenone at doses of 5, 15, and 50 mg/kg BID by oral gavage. PF-03882845 was dissolved in vehicle comprised of 0.5% methyl cellulose, 0.1% polysorbate 80 in water.

Urine collection
----------------

Twenty-four hours urine samples were collected at baseline, on Days 14 and 25 of treatment. Urine volume was recorded and samples were utilized for creatinine and albumin concentrations.

Plasma/serum collection
-----------------------

Rats were bled at baseline for plasma K^+^ measurement. Following the first dose of the respective compounds, rats were bled at 1, 2, 4, 7 h for drug levels measurements. On Day 14 of treatment, rats were bled at 7 h post the first dose of the day for plasma drug levels and serum K^+^ measurements. Additionally on Day 26, rats were bled at 1, 2, 4, 7 h post-dose for plasma drug levels measurement. On Day 27 (at necropsy, \~16 h post final dose), rats were bled for measurement of serum K^+^ and plasma drug levels measurements.

Tissue collection
-----------------

On Day 27 rats were euthanized with CO~2~, in accordance with IACUC guidelines and regulations at Pfizer Inc (Groton, CT). Kidney was removed, and weighed. A section of kidney was fixed in 10% formalin for histological analysis and a second portion of kidney (200 mg) was stored in a RNA stabilization reagent (RNAlater, Qiagen) for gene expression analysis.

Histology
---------

Kidney sections were stained with a rabbit anti-collagen-IV antibody (Thermo Scientific) and detected with an anti-rabbit antibody conjugated to horseradish peroxidase (HRP). Slides were counterstained with hematoxylin. Data were expressed as percent collagen IV staining of the kidney cortex.

RT-PCR
------

Kidney samples (\~30 mg) were removed from RNAlater and homogenized in 700 μ L of buffer RLT for RNA purification using an RNeasy Mini Kit (Qiagen) with on-column DNase treatment. Purified RNA was quantitated by NanoDrop. Samples (20 ng) were analyzed by RT-PCR to assess relative mRNA expression of Collagen-IV (*Col4a1*), osteopontin (*Spp1*), interleukin-6 (*Il-6*), intercellular adhesion molecule 1 (*Icam-1*), monocyte chemoattractant protein-1 (*Mcp-1*) and transforming growth factor β-1 (*Tgf-β 1*) using gene expression assays (Applied Biosystems), RNA to Ct Kit (Applied Biosystems) and the SDS-7900HT (Applied Biosystems). Expression data were normalized to mRNA expression of the endogenous control hypoxanthine phosphoribosyltransferase 1 (*Hprt1*). Data were expressed as relative quantitation (RQ) units using Veh Sham animal No. 2 as comparator (ie RQ equal to "1").

Biomarker measurements
----------------------

Serum K^+^, urinary albumin and creatinine were measured using the Siemens Advia 2400 Chemistry Analyzer and reagents from Siemens Healthcare Diagnostics (Washington, DC). UACR was calculated as the ratio of urinary albumin concentration to creatinine concentration. Plasma osteopontin was measured on day 27 samples using an enzyme immunoadsorbent assay (Enzo Life Sciences, Inc., Farmingdale NY).

Compound exposure
-----------------

Plasma was analyzed for eplerenone or PF-03882845 using a non-GLP LC/MS/MS method. All calculations were performed in Watson LIMS (v7.2, Thermo, Inc, Philadelphia, PA) and individual data were used in all pharmacokinetic analyses. The area under the plasma concentration-time curve (AUC(0-last)) was estimated using the linear trapezoidal rule.

Pharmacokinetic/pharmacodynamic (PK-PD) modeling for study A and study B
------------------------------------------------------------------------

Population PK-PD modeling was conducted in NONMEM (version VI 2.0; GloboMax LLC. Hanover, MD). Analysis was conducted in a piece-wise manner whereby individual pharmacokinetic parameters estimated for each animal in step 1 were fixed during estimation of pharmacodynamic parameters in the second step.

The pharmacokinetics of eplerenone and PF-03882845 were characterized with one and two compartmental models, respectively. In both cases first order absorption and elimination was assumed. Decreases in exposure upon multiple dosing for both compounds were characterized assuming that clearance was induced between Days 1 and 7 and remained constant thereafter. Population variance on the rate of absorption, elimination and volume of distribution were assumed in order to provide the best possible description of exposure in individual animals. Individual pharmacokinetic parameter estimates were carried forward in modeling the PK-PD relationship to UACR and serum K^+^.

Increases in UACR in vehicle controls were modeled with an indirect response model where the initial value (i.e., UACR at the start of the study) represents a non-steady state condition that varies between individual rats. Drug effect was parameterized such that the increase in UACR was inhibited via an indirect response *I*~max~ model (Equation 1). Both eplerenone and PF-03882845 PK-PD data were modeled simultaneously. The *I*~max~, *K*~in~, and *K*~out~ parameters were assumed to be drug independent and only the IC~50~ parameter was assumed to be drug dependent. $$\frac{dUACR}{dt} = K_{\text{in}} \times \left\lbrack {1 - \frac{I_{\text{max}} \times C}{C + IC_{50}}} \right\rbrack - K_{\text{out}} \times \text{UACR}$$

For modeling purposes, serum K^+^ data were transformed according to Equation 2. This formula allows for the calculation of drug-induced changes in serum K^+^ (from baseline), which are above and beyond that measured in the vehicle group. T × T and T × 0 represent the measured serum K^+^ in each drug treated individual at times equal to "T" and 0, respectively. VehT and Veh0 represent the mean measured serum K^+^ in the vehicle group at times equal to "T" and 0, respectively. $$\Delta\text{serum}K = (\text{T} \times \text{T} - \text{T} \times 0) - (\text{VehT-Veh}0)$$

The relationship between drug exposure and Δ serum K^+^ was modeled using a modified indirect response model whereby drug creates a concentration-dependent input rate (Equation 3). Both eplerenone and PF-03882845 PK-PD data were modeled simultaneously. The *K*~in,\ max~, and *K*~out~ parameters were assumed to be drug independent and only the EC~50~ parameter was assumed to be drug dependent. $$\begin{array}{l}
{\frac{d\Delta\text{serum}K}{dt} = K_{\text{in}} - K_{\text{out}} \times \Delta\text{serum}K;\text{where }K_{\text{in}}} \\
{\text{~~~~~~~~~~~~~~~~~} = \frac{K_{\text{in},\text{ max}} \times C}{C + EC_{50}}} \\
\end{array}$$

Acute effect of MR antagonists on urinary Na^+^/K^+^ ratio
----------------------------------------------------------

Male, carotid artery cannulated, Sprague Dawley (SD) rats between 11 and 12 weeks of age were obtained (Charles River, MA), singly housed and acclimated in metabolic chambers for one week prior to the start of the experiment. Water and food (Purina 5001 pellets) were provided *ad-libitum* throughout the study. In one study, rats were randomly assigned to receive either vehicle (0.5% methyl cellulose, 0.1% polysorbate 80) alone or eplerenone at one of 3 doses: 5, 30 or 300 mg/kg. In a second study, rats were randomly assigned to receive either vehicle (0.5% methyl cellulose, 0.1% polysorbate 80) or PF-03882845 at one of 3 doses: 3, 10 and 30 mg/kg. On the evening prior to treatment administration, baseline urine was collected from 4 pm until 8 am on the day of treatment. Animals were then orally gavaged with their respective treatments at 8 am and urine collected at intervals of 0--2, 2--4, and 4--7 h post dose. After collection, urine was stored at −80°C until analyzed. Baseline blood was collected from carotid artery cannulas prior to dosing, and at 1, 2, 4, and 7 h post dose. Samples were centrifuged and plasma was collected and stored at −80°C for compound exposure measurements using the methodology described above. Urine sodium and K^+^ were measured using the Siemens Advia 2400 Chemistry Analyzer with reagents from Siemens Healthcare Diagnostics. Data were expressed as urinary Na^+^/K^+^ ratio.

PK modeling for eplerenone
--------------------------

A two compartment distribution model with zero order absorption was used (1 h duration = observed Tmax). Clearance (CL) was estimated as a function of dose: $$\text{CL} = {(\text{THETA}{(1)}^{\ast}{(30/\text{DOSE})}^{\ast \ast}\text{PWR})}^{\ast}\text{EXP}(\text{ETA}(1))$$ where Theta(1) is CL at 30 mg/kg, and PWR is a power function allowing non-linear change in CL with dose. Conditional estimates of CL, V1, and Q were obtained. A proportional residual error model was used.

PK modeling for PF-03882845
---------------------------

A one compartment distribution model with first order absorption was used. Conditional estimates of KA, CL, and V1 were obtained. A proportional residual error model was used.

PK/PD modeling of urinary Na^+^/K^+^
------------------------------------

A two compartment linear model with first order absorption was used for both drugs. Conditional PK parameter estimates were read in with the input data. For PF-03882845, drug was dosed into compartment 1 (depot); Q was fixed to 0 and V2 was fixed to 1. For eplerenone, KA was fixed to 1 and drug was "infused" into compartment 2 over 1 h. The PD endpoint was the "double delta" in urinary Na^+^/K^+^ ratio (measured at the midpoint of the urine collection interval). Mean vehicle Na^+^/K^+^ ratio at time = 0 (Veh0) and at each urine collection interval (VehT) was estimated using vehicle data from both drug studies combined. Individual animal Na^+^/K^+^ ratio observed at time = 0 (T × 0) and at the midpoint of collection intervals (T × T) were used to calculate the "double delta" change in Na^+^/K^+^ ratio as follows: $$\text{DDresponse} = (\text{TxT-Tx0}) - (\text{VehT-Veh}0)$$

Using this approach each animal\'s time zero response = 0.

Statistical analyses
--------------------

UACR and serum K^+^ data were analyzed using a mixed ANOVA model accounting for repeated measures where treatment group, days post operation and treatment day interaction effect were introduced as a fixed factor whereas the animal factor was considered as a random effect nested in the treatment factor. The baseline value for each animal was introduced as a covariate. The primary comparisons were vehicle sham group vs. the other four groups and the vehicle aldosterone group vs. treatment groups. A two-sided 5% test was conducted.

For Study A and Study B, kidney gene expression data, collagen IV staining data and plasma osteopontin data were analyzed with a One-Way ANOVA and a Tukey post test using GraphPad Prism 5. When unequal variances were observed, data were log-transformed prior to analysis. The primary comparisons were vehicle sham group vs. the other four groups and the vehicle aldosterone group vs. treatment groups.

Results {#s3}
=======

Potency of PF-03882845 and eplerenone
-------------------------------------

PF-03882845 exhibited a greater potency compared to eplerenone in a serum free functional reporter assay utilizing the human MR ligand binding domain \[PF-03882845 geometric mean IC~50~ = 0.755 nM (90% confidence interval: 0.501--1.11 nM; *n* = 6), eplerenone IC~50~ = 109 nM (90% confidence interval: 79.3--150 nM; *n* = 6)\].

Effect of eplerenone and PF-03882845 on UACR and serum K^+^
-----------------------------------------------------------

Baseline UACR levels were not different amongst groups. Aldosterone infusion increased UACR levels relative to the vehicle sham group in both Study A and Study B by Day 14 (Figures [1A](#F1){ref-type="fig"}, [2A](#F2){ref-type="fig"}, respectively). This effect was more pronounced by Day 26 (Figures [1B](#F1){ref-type="fig"}, [2B](#F2){ref-type="fig"}, respectively). The highest dose of eplerenone (450 mg/kg BID) prevented the increase on Days 14 and 26 of treatment (Figures [1A,B](#F1){ref-type="fig"}) while all doses of PF-03882845 were efficacious in blunting UACR elevations (Figures [2A,B](#F2){ref-type="fig"}). Aldosterone decreased serum K^+^ on Days 14 and 26 in Study A (Figures [3A,B](#F3){ref-type="fig"}) but only on Day 26 in Study B (Figures [4A,B](#F4){ref-type="fig"}). By Day 26, eplerenone prevented the aldosterone-induced decrease in serum K^+^ at the doses of 50 mg/kg and 450 mg/kg BID (Figure [3B](#F3){ref-type="fig"}). A similar effect was observed with PF-03882845 at the highest dose tested (50 mg/kg BID; Figure [4](#F4){ref-type="fig"}).

![**Effect of eplerenone on UACR on day 14 (A) and day 26 (B).** Data are represented as mean ± standard error of the mean. See Materials and Methods for statistical analysis. ^\*^Indicates a significant difference from the vehicle sham (Veh Sham) group; ^\#^Indicates a significant difference from the vehicle + aldosterone (Veh Aldo) group.](fphar-04-00115-g0001){#F1}

![**Effect of PF-03882845 on UACR on day 14 (A) and day 26 (B).** Data are represented as mean ± standard error of the mean. See Materials and Methods for statistical analysis. ^\*^Indicates a significant difference from the vehicle sham (Veh Sham) group; ^\#^Indicates a significant difference from the vehicle + aldosterone (Veh Aldo) group.](fphar-04-00115-g0002){#F2}

![**Effect of eplerenone on serum K^+^ on day 14 (A) and day 26 (B).** Data are represented as mean ± standard error of the mean. See Materials and Methods for statistical analysis. ^\*^Indicates a significant difference from the vehicle sham (Veh Sham) group; ^\#^ Indicates a significant difference from the vehicle + aldosterone (Veh Aldo) group.](fphar-04-00115-g0003){#F3}

![**Effect of PF-03882845 on serum K^+^ on day 14 (A) and day 26 (B).** Data are represented as mean ± standard error of the mean. See Materials and Methods for statistical analysis. ^\*^Indicates a significant difference from the vehicle sham (Veh Sham) group; ^\#^Indicates a significant difference from the vehicle + aldosterone (Veh Aldo) group.](fphar-04-00115-g0004){#F4}

PK-PD modeling of UACR and serum K^+^
-------------------------------------

Model estimated values of the EC~50~ for UACR and for serum K^+^ are depicted in Figure [5](#F5){ref-type="fig"} and Table [1](#T1){ref-type="table"}. Eplerenone and PF-03882845 resulted in overlapping concentration effect curves for serum K^+^ (Figure [5B](#F5){ref-type="fig"}) and the derived EC~50~ values were not significantly different (Table [1](#T1){ref-type="table"}). By contrast, PF-03882845 was more potent than eplerenone in preventing the rise in UACR as observed in the modeled concentration-effect curves (Figure [5A](#F5){ref-type="fig"}). The resulting EC~50~ was 64-fold lower compared to eplerenone (Figure [5A](#F5){ref-type="fig"} and Table [1](#T1){ref-type="table"}). The therapeutic index (TI), calculated as the ratio of EC~50~ for increasing serum K^+^ to the EC~50~ for suppressing UACR, was 1.47 for eplerenone and 84 for PF-03882845 (Table [1](#T1){ref-type="table"}).

![**PK-PD modeling of UACR and serum potassium.** Concentration-effect curves of eplerenone (gray lines) and PF-03882845 (black lines) for UACR **(A)** and serum K^+^ **(B)** following 27 days of treatment. Dashed lines indicate the 95% upper and lower confidence intervals. Data were modeled using an indirect response model. A double delta equation was used to express the pharmacodynamic response for serum K^+^.](fphar-04-00115-g0005){#F5}

###### 

**Chronic effect of PF-03882845 and eplerenone on UACR and serum K^+^**.

  **Compound**   **Endpoint**   **EC~50~ nM (Total conc)**   **95% CI lower limit**   **95% CI upper limit**   **fEC~50~ nM (corrected for for protein binding)[^a^](#TN1a){ref-type="table-fn"}**   **fEC~50~/*in vitro* potency[^b^](#TN1b){ref-type="table-fn"}**   **TI (95% CI)[^c^](#TN1c){ref-type="table-fn"}**
  -------------- -------------- ---------------------------- ------------------------ ------------------------ ------------------------------------------------------------------------------------- ----------------------------------------------------------------- --------------------------------------------------
  PF-03882845    Serum K^+^     874                          75.5                     1671                     3.32                                                                                  4.43                                                              84.0
                 UACR           10.4                         2.36                     18.5                     0.0395                                                                                0.0527                                                            (4.1--710)
  Eplerenone     Serum K^+^     988                          134                      1843                     672                                                                                   6.16                                                              1.47
                 UACR           671                          411                      932                      456                                                                                   4.19                                                              (0.14--4.5)

Data expressed as EC~50~ with 95% confidence interval (CI).

fEC~50~: EC~50~ multiplied by fraction unbound: PF-03882845: 0.0038; Eplerenone: 0.68.

In vitro potency: PF-03882845: 0.75 nM; Eplerenone: 109 nM.

Therapeutic index (TI) calculated as the ratio of "EC~50~/in vitro potency" for serum K^+^ to "EC~50~/in vitro potency" for UACR.

Effect of PF-03882845 and eplerenone on collagen IV staining in kidney
----------------------------------------------------------------------

Continuous infusion with aldosterone significantly increased collagen IV staining in kidney cortex (Figures [6B,F](#F6){ref-type="fig"}) vs. the vehicle sham group (Figures [6A,E](#F6){ref-type="fig"}) in Study A and Study B, respectively. Eplerenone prevented the increase in collagen IV staining at the 450 mg/kg BID dose only (Figures [6C,D,J](#F6){ref-type="fig"}) while all three doses of PF-03882845 were efficacious (Figures [6G--I](#F6){ref-type="fig"}, [6K](#F6){ref-type="fig"}).

![**Representative images of collagen IV immunohistochemical localization in kidney cortex.** Study A, vehicle sham **(A)**, vehicle + aldosterone **(B)**, 50 mg/kg BID eplerenone **(C)**, and 450 mg/kg BID eplerenone **(D)**, groups following 27 days of treatment; and Study B, kidney cortex from sham vehicle **(E)**, vehicle + aldosterone **(F)**, 5 mg/kg BID PF-03882845 **(G)**, 15 mg/kg BID PF-03882845 **(H)**, and 50 mg/kg BID PF-03882845 **(I)** following 27 days of treatment. Data expressed as % collagen IV staining in kidney cortex and represented as mean ± standard error of the mean: Study A **(J)** and Study B **(K)**. See Materials and Methods for statistical analysis. ^\*^Indicates a significant difference from the vehicle sham (Veh Sham) group; ^\#^Indicates a significant difference from the vehicle + aldosterone (Veh Aldo) group.](fphar-04-00115-g0006){#F6}

Effect of PF-03882845 and eplerenone on gene expression in kidney
-----------------------------------------------------------------

In studies A and B, aldosterone significantly increased mRNA expression of collagen 4a1, transforming growth factor β-1 (*Tgf-β 1*), interleukin-6 (*Il-6*), intercellular adhesion molecule-1 (*Icam-1*), monocyte chemoattractant protein-1 (*Mcp-1*), and osteopontin (*Spp1*) in the kidney on Day 27. This was prevented by PF-03882845 at all doses tested (Table [2](#T2){ref-type="table"}), while eplerenone prevented the rise in these genes only at the highest dose tested (4.0 mg/kg BID) (Table [3](#T3){ref-type="table"}).

###### 

**Effect of PF-03882845 on relative gene expression in kidney on day 27**.

  **PF-03882845**   **Veh sham**   **Veh aldo**                                   **PF-03882845 5 mg/kg BID**                     **PF-03882845 15 mg/kg BID**                    **PF-03882845 50 mg/kg BID**
  ----------------- -------------- ---------------------------------------------- ----------------------------------------------- ----------------------------------------------- -----------------------------------------------
  *Tgf-1β*          0.95 ± 0.039   1.7 ± 0.14[^\*^](#TN2b){ref-type="table-fn"}   1.0 ± 0.088[^ȧ^](#TN2a){ref-type="table-fn"}    0.93 ± 0.092[^ȧ^](#TN2a){ref-type="table-fn"}   0.89 ± 0.071[^ȧ^](#TN2a){ref-type="table-fn"}
  *Col4a1*          0.92 ± 0.051   1.5 ± 0.11[^\*^](#TN2b){ref-type="table-fn"}   1.0 ± 0.099[^ȧ^](#TN2a){ref-type="table-fn"}    1.1 ± 0.12[^ȧ^](#TN2a){ref-type="table-fn"}     0.94 ± 0.059[^ȧ^](#TN2a){ref-type="table-fn"}
  *Il-6*            1.0 ± 0.14     6.6 ± 0.68[^\*^](#TN2b){ref-type="table-fn"}   1.6 ± 0.29[^ȧ^](#TN2a){ref-type="table-fn"}     1.1 ± 0.18[^ȧ^](#TN2a){ref-type="table-fn"}     1.2 ± 0.18[^ȧ^](#TN2a){ref-type="table-fn"}
  *Icam-1*          1.1 ± 0.050    1.8 ± 0.14[^\*^](#TN2b){ref-type="table-fn"}   1.1 ± 0.077[^ȧ^](#TN2a){ref-type="table-fn"}    1.2 ± 0.12[^ȧ^](#TN2a){ref-type="table-fn"}     1.2 ± 0.056[^ȧ^](#TN2a){ref-type="table-fn"}
  *Mcp-1*           0.96 ± 0.089   1.8 ± 0.26[^\*^](#TN2b){ref-type="table-fn"}   0.95 ± 0.082[^ȧ^](#TN2a){ref-type="table-fn"}   0.64 ± 0.070[^ȧ^](#TN2a){ref-type="table-fn"}   0.76 ± 0.090[^ȧ^](#TN2a){ref-type="table-fn"}
  *Spp1*            0.92 ± 0.11    11 ± 1.9[^\*^](#TN2b){ref-type="table-fn"}     1.3 ± 0.23[^ȧ^](#TN2a){ref-type="table-fn"}     0.73 ± 0.081[^ȧ^](#TN2a){ref-type="table-fn"}   0.60 ± 0.20[^ȧ^](#TN2a){ref-type="table-fn"}

Values are mean relative quantitation ± standard error of the mean, n = 8--10/group. One-Way ANOVA with Tukey\'s post-hoc analysis was performed.

Significantly different from vehicle sham (Veh sham);

significantly different from vehicle + aldosterone (Veh aldo).

###### 

**Effect of eplerenone on gene expression in kidney on day 27**.

  **Eplerenone**   **Veh sham**   **Veh aldo**                                   **Eplerenone 15 mg/kg BID**                     **Eplerenone 50 mg/kg BID**                    **Eplerenone 4.0 mg/kg BID**
  ---------------- -------------- ---------------------------------------------- ----------------------------------------------- ---------------------------------------------- ----------------------------------------------
  *Tgf-1β*         1.1 ± 0.071    1.9 ± 0.20[^\*^](#TN3a){ref-type="table-fn"}   1.7 ± 0.12                                      1.6 ± 0.20                                     1.2 ± 0.039[^∧^](#TN3b){ref-type="table-fn"}
  *Col4a1*         1.0 ± 0.050    1.6 ± 0.16[^\*^](#TN3a){ref-type="table-fn"}   1.4 ± 0.087[^\*^](#TN3a){ref-type="table-fn"}   1.2 ± 0.057                                    1.1 ± 0.050[^∧^](#TN3b){ref-type="table-fn"}
  *Il-6*           1.1 ± 0.25     6.3 ± 1.5[^\*^](#TN3a){ref-type="table-fn"}    5.0 ± 0.89[^\*^](#TN3a){ref-type="table-fn"}    5.5 ± 1.4                                      3.5 ± 1.5
  *Icam-1*         1.2 ± 0.047    1.9 ± 0.18[^\*^](#TN3a){ref-type="table-fn"}   1.9 ± 0.20[^\*^](#TN3a){ref-type="table-fn"}    1.8 ± 0.25                                     1.2 ± 0.060[^∧^](#TN3b){ref-type="table-fn"}
  *Mcp-1*          1.1 ± 0.10     2.2 ± 0.25[^\*^](#TN3a){ref-type="table-fn"}   2.6 ± 0.56[^\*^](#TN3a){ref-type="table-fn"}    2.6 ± 0.54[^\*^](#TN3a){ref-type="table-fn"}   1.4 ± 0.26
  *Spp1*           2.0 ± 0.33     46 ± 11[^\*^](#TN3a){ref-type="table-fn"}      25 ± 5.3[^\*^](#TN3a){ref-type="table-fn"}      30 ± 9.7[^\*^](#TN3a){ref-type="table-fn"}     3.2 ± 0.75[^∧^](#TN3b){ref-type="table-fn"}

Values are mean realtive quantitation ± standard error of the mean, n = 10--11/group. One-way ANOVA with Tukey\'s post-hoc analysis was performed.

Significantly different from vehicle sham (Veh sham);

Significantly different from vehicle + aldosterone (Veh aldo).

Effect of PF-03882845 and eplerenone on plasma osteopontin
----------------------------------------------------------

Aldosterone increased plasma osteopontin levels in Study A (vehicle: 93.6 ± 16.4 ng/ml; vehicle + aldosterone: 345 ± 205 ng/ml (mean ± SEM)) and this effect was blunted by eplerenone at the 450 mg/kg BID dose (62.2 ± 7.98 ng/ml), while the doses of 15 or 50 mg/kg BID were not different from the vehicle + aldosterone group (eplerenone 15 mg/kg BID: 204 ± 35.1; eplerenone 50 mg/kg BID: 234 ± 85.6 ng/ml). In study B, aldosterone increased plasma osteopontin levels (vehicle: 87.3 ± 13.9 ng/ml; vehicle + aldosterone: 494 ± 90.1 ng/ml). This effect was suppressed at all doses of PF-03882845 (PF-03882845.5 mg/kg BID: 108 ± 13.5, 15 mg/kg BID: 77.1 ± 15.7 and 50 mg/kg BID: 82.4 ± 17.0 ng/ml, respectively).

Acute effect of PF-03882845 and eplerenone on urinary Na^+^/K^+^ ratio
----------------------------------------------------------------------

Urinary Na^+^/K^+^ ratio was assessed in SD rats following single doses of PF-03882845 or eplerenone. Concentration-effect curves were generated using an indirect response model. In agreement with the chronic effects of these compounds on serum K^+^ levels, the EC~50~ values for the acute effect on urinary Na^+^/K^+^ ratios were not different when corrected for the respective free fraction and *in vitro* potency (PF-03882845 (mean \[95% confidence interval\]: 3.10 \[1.58--4.62\]) and eplerenone (5.92 \[2.22--9.63\]) (Figure [7](#F7){ref-type="fig"}).

![**Effect of eplerenone and PF-03882845 on urinary Na^+^/K^+^ ratio.** SD rats received single doses of 0, 5, 30, or 3.0 mg/kg eplerenone or 0, 3, 10, or 30 mg/kg PF-03882845 and urinary Na^+^/K^+^ was assessed at 0--2, 2--4, and 4--7 h post-dose. Both compounds yielded analogous concentration-effect curves for urinary Na^+^/K^+^. Data were expressed as free concentration normalized to *in vitro* IC50 (0.75 nM for PF-03882845 and 109 nM for eplerenone in a serum free assay). Data were modeled using an indirect response model. Dashed lines indicate the 95% lower and upper confidence boundary limits.](fphar-04-00115-g0007){#F7}

Discussion {#s4}
==========

We investigated whether PF-03882845, a novel non-steroidal MR antagonist, differentiates from traditional steroidal MR antagonists, such as eplerenone. Our findings indicate that PF-03882845 exhibits a greater TI, calculated as the ratio of the EC~50~ for increasing serum K^+^ to the EC~50~ for UACR lowering, compared to eplerenone. Thus, our results support the development of PF-03882845 for the treatment of diabetic nephropathy, a condition in which the patient is particularly at risk for hyperkalemia.

Aldosterone binding to the MR mediates sodium and water retention in exchange for K^+^ secretion in the renal tubules. These effects appear to be downstream of the serum- and glucocorticoid-inducible kinase-1 (SGK1) (Lang et al., [@B27]; Terada et al., [@B49]). Indeed, aldosterone has been demonstrated to stimulate *Sgk1* mRNA expression (Naray-Fejes-Toth et al., [@B36]) and phosphorylation (Flores et al., [@B18]) in cortical collecting duct cells. Activated SGK1 inhibits turnover of the epithelial sodium channel (ENaC) thereby enhancing ENaC abundance at the plasma membrane (Butterworth et al., [@B10]) via phosphorylation and inhibition of the ubiquitinase Nedd4-2 which marks ENaC for proteasomal degradation (Flores et al., [@B18]). Sodium transport is also regulated by the With-No-K (lysine) kinase (WNK) family of kinases amongst which WNK4 has been demonstrated to phosphorylate and inhibit ENaC and the Na^+^ and Cl^−^ cotransporter (NCC) (Hoorn et al., [@B23]). In turn, WNK4 is phosphorylated and inhibited by SGK1 and by the "long form"-WNK1 (L-WNK1). Thus, aldosterone increases Na^+^ retention via SGK1 mediated phosphorylation/inhibition of WNK4, thereby relieving inhibition of ENaC and NCC (Hoorn et al., [@B23]; Vallon et al., [@B50]).

Aldosterone modulates K^+^ secretion via SGK1 upregulation of the renal outer medullary potassium (ROMK) channels in the thick ascending limb of Henle\'s loop, the distal tubule and in cortical collecting duct cells. L-WNK1 and WNK4 downregulate ROMK by stimulating clathrin-dependent endocytosis and this is abrogated by SGK1 mediated phosphorylation of Wnk4 (Welling and Ho, [@B53]). In addition to effects on ENaC and ROMK, aldosterone increases K^+^ secretion in exchange for sodium uptake via the basolateral Na^+^/K^+^ ATPase (Djelidi et al., [@B12]).

In the present study, aldosterone treatment of uninephrectomized rats depressed serum K^+^ levels as anticipated. In contrast, treatment with the MR antagonists blunted this effect, likely through preventing aldosterone-induction of ENaC, ROMK and the Na^+^/K^+^ ATPase. PK-PD modeling demonstrated that PF-03882845 and eplerenone were equipotent for increasing serum K^+^ levels relative to the vehicle + aldosterone group and for increasing the urinary Na^+^/K^+^ ratio following single doses in normal SD rats. Effects of MR antagonists on urinary Na^+^/K^+^ ratio have been well-characterized in rodents as well as humans (McInnes et al., [@B32]). Early on, Kagawa demonstrated blockade of mineralocorticoid activity in adrenalectomized rats by measuring urinary Na^+^/K^+^ ratio (Kagawa, [@B25]). This method was further simplified by Brandish et al. who revealed similar findings in rats with intact adrenal glands (Brandish et al., [@B8]). We have previously demonstrated translatability of this biomarker from rat to humans using preclinical and clinical data generated with eplerenone (Eudy et al., [@B16]). Our present findings extend these results by demonstrating similar concentration effect curves for urinary Na^+^/K^+^ ratio generated in normal SD rats following single doses of MR antagonists, and for serum K^+^ in an animal model of nephropathy following chronic exposure to the compounds. Thus, urinary Na^+^/K^+^ ratio in a healthy state appears to be a useful biomarker for assessing the risk of hyperkalemia in a renally compromised condition.

Interestingly, PK-PD modeling revealed that PF-03882845 was more potent than eplerenone in lowering UACR despite equipotent effects on serum potassium, thereby yielding a 57-fold greater therapeutic index against hyperkalemia compared to eplerenone. Albuminuria, a widely used surrogate biomarker of renal damage, has been previously demonstrated to be decreased by treatment with MR antagonists in patients with nephropathy (Sato et al., [@B45]; Epstein et al., [@B14]) and rodents with renal impairment (Blasi et al., [@B6]), supporting its modulation by aldosterone. Our results agree with these findings, and further highlight the potential of PF-03882845 in preventing/reducing renal damage, while posing less risk for hyperkalemia compared to a traditional MR antagonist. Concurrent with its effect on UACR, PF-03882845 was more potent than eplerenone in suppressing collagen IV gene and protein expression in kidney cortex. Collagen IV has been associated with glomerulosclerosis in experimental models (Floege et al., [@B17]; Bergijk et al., [@B2]; Lee et al., [@B28]) and humans (Kim et al., [@B26]; Tamsma et al., [@B48]; Esposito et al., [@B15]) with kidney disease. Renal biopsies from patients with diabetic nephropathy indicated a clear increase in α 2 type IV collagen gene and protein in glomeruli compared to controls (Adler et al., [@B1]). Importantly, aldosterone has been shown to stimulate collagen synthesis in rat renal fibroblasts (Nagai et al., [@B35]) and aldosterone infusion stimulated collagen III gene expression as assessed by *in situ* hybridization (Blasi et al., [@B6]). We expand on these findings by demonstrating increases of collagen IV gene and protein expression in kidney cortex with aldosterone infusion, and its blunting by the novel MR antagonist PF-03882845. Furthermore, our data indicate a greater potency of PF-03882845 compared to eplerenone for suppressing aldosterone-induced expression of proinflammatory and profibrotic genes in the kidney such as *Tgf-β*, *Il-6, Icam-1*, *Mcp-1 and Spp1*. ICAM-1 has been implicated in glomerular inflammation (Riser et al., [@B43]). Il-6 has been shown to upregulate *MCP-1* in human mesangial cells (Coletta et al., [@B11]). The latter was upregulated in urine of patients with diabetic nephropathy (DN) (Wada et al., [@B51]) and was decreased by spironolactone treatment (Takebayashi et al., [@B47]) suggesting regulation by the MR. TGF-β 1 has been demonstrated to reduce collagenase production thereby leading to accumulation of extracellular matrix components (Wolf, [@B54]). Importantly, Tgf-β 1 is increased in plasma of type 2 diabetics (Pfeiffer et al., [@B39]) and urine of type 2 diabetics with clinical diabetic nephropathy (Bertoluci et al., [@B4]) further supporting its role in the pathogenesis of this disease. In accordance with our findings, aldosterone infusion has been shown to increase TGF-β 1 protein expression in rat kidney (Juknevicius et al., [@B24]) and both TGF-β 1 and aldosterone independently stimulated connective tissue growth factor (CTGF), an inducer of renal fibroblast growth and synthesis of extracellular matrix proteins (Yokoi et al., [@B56]). In the present studies, aldosterone infusion also resulted in an increased intra-renal gene expression of osteopontin (*Spp1*), an extracellular matrix protein, chemokine and growth factor recently shown to be regulated by the MR in renal mesangial cells (Gauer et al., [@B19]). This effect was prevented more potently by PF-03882845 as compared to eplerenone. Importantly, plasma levels of osteopontin mirrored these findings. These results further support a greater potency of PF-03882845 vs. eplerenone in preventing renal damage as plasma levels of osteopontin have been shown to correlate with progression of diabetic nephropathy (Yamaguchi et al., [@B55]).

While our results clearly indicate a greater potency of PF-03882845 in reducing UACR compared to eplerenone, leading to an increased TI against hyperkalemia, mechanisms underlying these findings are yet to be determined. At least 3 hypotheses may explain the present data. First, PF-03882845 may differentially affect coactivator recruitment in different cell types leading to a greater repression of profibrotic pathways. Second, a greater uptake of PF-03882845 relative to eplerenone in cell types involved in filtration and fibrosis such as mesangial cells and/or podocytes compared to epithelial cells that regulate electrolyte balance could account for these findings. However, to-date, no evidence of active uptake of PF-03882845 into cells has been demonstrated. Third, the increased potency of PF-03882845 against fibrosis may be driven through off-target effects. Recently, aldosterone has been demonstrated to elicit effects on vascular smooth muscle cells at physiological concentrations through the GPR30 receptor (Gros et al., [@B20]). Further work is warranted to elucidate these findings.

In conclusion, PF-03882845, a novel non-steroidal MR antagonist, appears to present less of a risk for hyperkalemia while maintaining efficacy in preventing renal damage in a rodent model of nephropathy. Should these results translate into humans, PF-03882845 may present a safe and efficacious alternative for the treatment of chronic kidney disease.
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